- Anthony Bozza sees more than 50% downside in Ligand Pharmaceuticals (LGND -3.1%), according to his fund's Q1 letter. The market, he says, overvalues the company's pipeline.
- iRhythm (IRTC -7%) has nearly 70% downside, says Bozza, noting a fancy valuation in the face of continuing losses and looming competitive threats.
- Source: Bloomberg
Ligand Pharma, iRhythm Tech new shorts at Lakeland Capital
Recommended For You
About LGND Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
LGND | - | - |
Ligand Pharmaceuticals Incorporated |